4-Methylpyrazole, in a dose producing inhibition of alcohol dehydrogenase (alcohol:NAD+ oxidoreductase, EC 1.1.1.1), was given alone or together with ethanol (10%) as sole drinking fluid to growing rats for up to 38 weeks. Their weight curves remained normal. Electron microscopy of liver, kidney, and heart revealed no changes related to treatment. Hematologic analysis showed normal values for blood and bone marrow. Several clinical chemical parameters showed no impairment of liver or kidney function, except for an enhancement of the microsomal drug-metabolizing activity after concurrent administration of 4-methylpyrazole and ethanol. A study on rats receiving 4-methylpyrazole and ethanol indicated a mutual interaction of the two compounds or the metabolites, leading to increased concentration in the blood of the compounds and reduced formation of 4-hydroxymethylpyrazole, the primary metabolite of 4-methylpyrazole. In monkeys, elimination of 4-methylpyrazole followed a linear course. 4-Hydroxymethylpyrazole accumulated to a level of at most 10% of that of 4-methylpyrazole. Concurrent administration of methanol inhibited the elimination of 4-methylpyrazole about 25%, and 4-methylpyrazole produced a profound inhibition of the oxidation of methanol. 4-Methylpyrazole, at a level in the plasma of more than 10 ,iM, prevented accumulation of the toxic metabolite formic acid in methanol-poisoned monkeys, and repeated injections of 4-methylpyrazole abolished methanol toxicity in monkeys receiving lethal doses of methanol. The present investigation indicates that 4-methylpyrazole, with its low toxicity and strong inhibition of alcohol oxidation, is a valuable tool for experimental studies of alcohol metabolism and its effects. It illustrates the usefulness of the monkey as a model to study 4-methylpyrazole activity and toxicity in light of its possible use for treating methanol poisoning in human beings.
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Alcoholism is a disease limited to human beings. It is therefore important to study the metabolism of ethanol in humans in order to provide a better understanding of the biochemical aspects of alcoholism. In 1963, Theorell and Yonetani (1) reported that pyrazole inhibits the action of horse liver alcohol dehydrogenase (alcohol:NAD+ oxidoreductase, EC 1.1.1.1) (ADH) in vitro by forming a complex with ADH and NAD+. In 1969 Li and Theorell (2) reported the kinetics of inhibition of human ADH by pyrazole and some substituted derivatives. They found that, as with the horse enzyme, these compounds form inactive ternary complexes by coupling with ADH and its coenzyme NAD+. In 1970 Blomstrand and Theorell (3) reported the use of 4-methylpyrazole (4-MP) in human beings in studies on ethanol oxidation. They emphasized that this type of inhibitor should be used as a valuable tool for elucidation of the effect of ethanol on different biochemical variables. It has also been suggested that 4-MP might be used in the treatment of methanol poisoning in humans (4) . 4 -MP has been used in some investigations in humans according to this early suggestion (5) (6) (7) . A wider use of (8) in clinical alcohol research has been hindered by the pronounced toxicity of its parent compound pyrazole (9) . 4 -MP is a more specific and much stronger inhibitor of ADH than pyrazole; for example, it does not (10) , in contrast to pyrazole (11) , inhibit catalase in vivo. It is thus important to have a detailed knowledge of the pharmacological and toxicological effects of 4-MP alone or in combination with ethanol (12) .
In the present study these effects have been extensively investigated in rats in a 38-week-long feeding experiment. Another part of the present work concerns the effects of 4-MP in the monkey, which is the only species (13) that is susceptible to methanol toxicity in the same manner as humans. This approach to treatment of methanol poisoning in humans with a specific inhibitor of ADH may significantly improve the therapeutic results. A full report of these investigations will be published elsewhere.
MATERIALS AND METHODS Unlabeled 4-MP was obtained from AB Labkemi (Gothenburg, Sweden) and was pure as shown by gas/liquid chromatography. Unlabeled 4-hydroxymethylpyrazole (4-OH-MP) and 4-carboxypyrazole were gifts from Astra-Ewos (S6dertalje, Sweden). All other reagents were of the highest available purity. Details of the synthesis and purification of 4-methyl [6-2H3,] pyrazole have been given (14) . 4-Methyl-['5N2]pyrazole was synthesized from 2-methyl-1,1,3,3-tetraethoxypropane and [15N2]hydrazine sulfate by a method described for the synthesis of 4-MP (15).
4-Hydroxymethyl[6-2H2]pyrazole (4-OH-[6-2H2]MP) was
synthesized from 4-carboxypyrazole after reduction with lithium aluminum deuteride. After derivatization with tbutyl-dimethylchlorosilane imidazole reagent, the material had a mass spectrum consistent with t-butyl-dimethylsilyl ether of 4-OH-MP with two atoms of deuterium in the molecule.
Assays. 4-MP in plasma was determined by a mass fragmentographic assay basically identical to that described (14) aminopyrine N-demethylase, and p-nitroanisol O-demethylase was determined (18) .
After 38 weeks, one animal from each group was anesthetized with ether, the abdomen was opened, and the animal was killed by exsanguination. The liver was perfused with 2% glutaraldehyde and samples for electron microscopy were taken through graded alcohols and then embedded in Epon (19) .
In an acute interaction study of 4 
RESULTS

Rat experiments
The rats showed no obvious clinical symptoms during the long-term administration of 4-MP and ethanol. There were no signs of intoxication and their activity seemed unimpaired. The mean daily doses of 4-MP and ethanol were calculated for the last 3 weeks in series I. This gave an average daily intake of 0.14 mmol of 4-MP and 0.18 mol of ethanol per kg. The mean values for the weight gain in the different groups are illustrated in Fig.  1 . During the last 3 weeks there was no significant difference among the different groups.
Hematocrit value and serum iron were within reference values of the control group. Hemoglobin was somewhat increased in groups E and M, and erythrocytes showed a slightly decreased concentration in group EM. Altogether, the hematological variables investigated indicated no damage of the bone marrow (Table 1 The rats were treated orally with 4-MP (50 mg/kg) or ethanol (4 g/kg) or both, and serum was collected 4 hr after the administration. Group mean value + SEM (n = 5).
and normal cell organelles (seen by electron microscopy) indicated that there was no damage of kidney function in any of the groups investigated.
The concentrations of ethanol and 4-MP in the long-term experiments at different time intervals are given in Table 2 . 4-MP partially inhibited the oxidation of ethanol, leading to a significantly higher blood ethanol concentration than in the rats that drank only ethanol. There was also, however, a higher concentration of 4-MP in the blood of rats drinking both ethanol and 4-MP than in the blood of rats drinking only 4-MP in the tap water.
In Table 3 olism. A dose of 50 mg/kg was shown to inhibit 14CO2 production from [14C]methanol in the monkey by 75% (20) . Monkeys C and H were two of a series of monkeys in which the effectiveness of 4-MP in reversing methanol toxicity was tested. The monkeys received 3 or 4 g of methanol per kg, which are potentially lethal doses for the cynomolgus monkey, and were allowed to develop signs of methanol toxicity. We observed an initial slight inebriation, then a latent period of no obvious distress, followed by vomiting, weakness, cold extremities, and general behavioral distress. Within a few hours after 4-MP injection, the monkeys showed recovery from the toxic syndrome; they were alert, strong, competitive, and hungry. Doses of 15 and 20 mg of 4-MP per kg in monkeys C and H were sufficient to rapidly decrease the formate levels to control and were effective for approximately 20 hr. After this initial dose in monkey H, 4-MP was administered twice a day, 2.5 mg/kg in the early morning and 7.5 mg/kg in the late afternoon (Fig. 3) . DISCUSSION The use of 4-MP in extensive investigations of ethanol metabolism in humans or in treatment of methanol or ethylene glycol poisoning in humans is hindered by the toxicity of pyrazole. It is, however, necessary to stress the difference between these two compounds in their toxic potential. Pyrazole (9, 11) is highly toxic, inducing weight loss, liver necrosis, and cytoxicity in other organs of rats and mice, especially when administered together with ethanol (9, 21, 22) . Toxicity was observed at doses necessary to inhibit ethanol metabolism in vivo. Toxicity has also been observed upon coadministration of pyrazole (100 mg/kg) and methanol in monkeys (23) .
In contrast to pyrazole, 4-MP is a relatively nontoxic compound in rats and mice, with no evidence of toxic effects on variables of clinical chemistry or of gross and microscopic pathology at a dose of 100 mg/kg daily for 4 weeks (8) or 12 mg/kg daily for 12 weeks in combination with ethanol (12) . In the present study, several clinical chemical variables indicated that neither 4-MP alone nor in combination with ethanol produced any liver damage (Table 1) . Electron microscopy of the livers from the different groups after 38 weeks did not reveal any lesions on the cell organelles. Electron microscopy was also carried out on hearts and kidneys from rats in the different groups after 38 weeks. No pathological lesions were revealed on the different cell organelles from these organs. The serum creatinine and electrolytes from rats of the different groups were all in the normal range. The osmolality of the serum was increased in groups E and EM, but this is due to the increased concentration of ethanol in these groups. Kidney function can thus be considered normal in the present investigation.
Chronic administration of ethanol together with an effective inhibitor of ADH, such as 4-MP, should create a metabolic situation in which the metabolic effects produced by influences on the NADH/NAD ratio within cytosol and mitochondria are less pronounced, albeit the effects of ethanol per se should be more pronounced through inhibition of the ADH system.
To further elucidate the mechanism of interaction between ethanol and 4-MP, we carried out an acute interaction study. From the results in Table 3 (27) .
Although 4-OH-MP has been shown to be an inhibitor of both human and rat liver ADH in vitro (28) , the relatively high Ki compared to that of 4-MP seems to preclude a significant contribution of 4-OH-MP to the inhibition of ethanol metabolism in these rats.
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